Ophiomics attending the European Congress of Pathology (ECP) Ophiomics is attending ECP from 3-7 of September in Basel, Switzerland. We are be presenting HepatoPredict with our partner and distributor Biocartis. Come visit us at Biocartis Booth Nr 22.

Our paper “A gene expression signature to select hepatocellular carcinoma patients for liver transplantation” is finally out and can be found here. This study published in Annals of Surgery is the first clinical validation of HepatoPredict, an algorithm combining biomarkers measured in liver tumor with clinical variables, to predict recurrence after liver transplantation.  In this collaborative

As part of our Liquid Biopsy development pipeline, we are identifying biomarkers and developing algorithms that can change the way liver cancer is detected and managed. The first paper for our liver cancer early detection liquid biopsy test is out, and can be found here. From the abstract: “… Combining our signature of 38 DNA

Another important step in the development of HepatoPredict and an occasion for celebration: HepatoPredict is now a registered medical device under the DIRECTIVE 98/79/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 October 1998 on in vitro diagnostic medical devices.

Our collaborator from the Cento Hospital Universitário de Lisboa Central (Hospital Curry Cabral) presented an oral communication and discussed our work on predicting relapse after liver transplantation to treat hepatocellular carcinoma at the 28th anual meeting of the European Surgical Association. Lots of discussion and interest.

If you are attending the annual meeting of the International Liver Transplantation Society, come hear about HepatoPredict on Saturday morning, Room 1 – Joana Vaz, PhD, our CSO and co-founder, will present the first batch of clinical validation results.

It is with great joy that we announce that Prof. Marina Berenguer joined Ophiomics’ advisory board.  (From ILTS site) Prof. Marina Berenguer is a Consultant Hepatologist at La Fe University Hospital, Valencia, (Spain). She trained in medicine at the University of Valencia, before completing a fellowship at the VA Medical Center / University of California

Ophiomics (PT) and Biocartis (BE) announce today that they have entered into a collaboration regarding HepatoPredict™, a prognostic test for liver cancer. HepatoPredict™ will be launched as a CE-marked IVD manual kit in Q1 2022. The partnership will initially focus on Biocartis’ commercialization of the manual kit in Europe. In a next stage, depending on

On the last days of 2021 Ophiomics launched the fabrication of its first “production-scale” lot of the HepatoPredict  kit, already in preparation for its anticipated commercial development in Q1 2022, and is now a registered manufacturer of medical devices. It seems impossible that 6 months ago we were still entertaining a different business model, where